Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 10/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 7/20 | 0.52 |
| ▸ | HPGD | P15428 | 7/20 | 0.52 |
| ▸ | MAPT | P10636 | 4/20 | 0.52 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.52 |
| ▸ | GAA | P10253 | 4/20 | 0.52 |
| ▸ | MEN1 | O00255 | 3/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.52 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.52 |
| ▸ | GLA | P06280 | 2/20 | 0.52 |
| ▸ | ATM | Q13315 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.52 |
| ▸ | GRM6 | O15303 | 1/20 | 0.52 |
| ▸ | GRM5 | P41594 | 1/20 | 0.52 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.49 |
| ▸ | PTPRC | P08575 | 1/20 | 0.47 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.47 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9031450 | 0.86 | ALDH1A1 (0.56) | ALDH1A1KDM4EHPGDMAPTHSD17B10 | |
| SCHEMBL9827009 | 0.84 | TRPM8 (0.51) | ALDH1A1KDM4EHPGDMAPTHSD17B10 | |
| SCHEMBL2060498 | 0.84 | GRM6 (0.65) | ALDH1A1KDM4EHPGDMAPTHSD17B10 | |
| SCHEMBL27592419 | 0.81 | ALDH1A1 (0.54) | ALDH1A1KDM4EHPGDMAPTHSD17B10 | |
| SCHEMBL2063437 | 0.78 | ALDH1A1 (0.48) | ALDH1A1KDM4EHPGDMAPTHSD17B10 | |
| SCHEMBL9826174 | 0.78 | PTPN1 (0.49) | ALDH1A1KDM4EHPGDMAPTHSD17B10 | |
| SCHEMBL23447121 | 0.77 | GRM6 (0.56) | ALDH1A1KDM4EHPGDMAPTHSD17B10 | |
| SCHEMBL3903415 | 0.77 | PTPN1 (0.76) | PTPRCPTPN2PTPN1 | |
| SCHEMBL27592498 | 0.76 | GRM6 (0.49) | ALDH1A1KDM4EHPGDMAPTHSD17B10 | |
| SCHEMBL9826124 | 0.75 | TRPM8 (0.55) | ALDH1A1KDM4EHPGDMAPTHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8148384-B2 | 8-bromo-2-[(3-hydroxyphenylamino)methyl]-3H-benzo[4,5]thieno[3,2-d]pyrimidin-4-one; ischemia reperfusion injury, inflammatory disease, retroviral infections, ischemia reperfusion injury, myocardial infarction | ABBOTT LABORATORIES (US) | 2012-04-03 | — | — | US | disclosed |
| US-20090030196-A1 | PIM KINASE INHIBITORS AS CANCER CHEMOTHERAPEUTICS | ABBOTT LABORATORIES (US) | 2009-01-29 | — | — | US | disclosed |
| WO-2008082840-A1 | PIM KINASE INHIBITORS AS CANCER CHEMOTHERAPEUTICS | ABBOTT LABORATORIES (US) | 2008-07-10 | — | — | WO | disclosed |
| WO-2008082839-A2 | PIM KINASE INHIBITORS AS CANCER CHEMOTHERAPEUTICS | ABBOTT LABORATORIES (US) | 2008-07-10 | — | — | WO | disclosed |
| US-20080161578-A1 | 8-bromo-2-[(3-hydroxyphenylamino)methyl]-3H-benzo[4,5]thieno[3,2-d]pyrimidin-4-one; increasing cell death of cancer cells, limiting tumor growth, decreasing metastasis, and prolonging the survival of tumor-bearing animals | ABBOTT LABORATORIES (US) | 2008-07-03 | — | — | US | disclosed |
| US-20080161559-A1 | PIM KINASE INHIBITORS AS CANCER CHEMOTHERAPEUTICS | ABBOTT LABORATORIES (US) | 2008-07-03 | — | — | US | disclosed |
| US-20080004325-A1 | PTP1B inhibitors | WYETH (US) | 2008-01-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080004325-A1 | PTP1B inhibitors | PTPA, PTPRJ, PTPRR | ALDH1A1 1266/4885KDM4E 1238/4885HPGD 3761/4885 |
| US-20080161578-A1 | 8-bromo-2-[(3-hydroxyphenylamino)methyl]-3H-benzo[4,5]thieno[3,2-d]pyrimidin-4-one; increasing cell death of cancer cells, limiting tumor growth, decreasing metastasis, and prolonging the survival of tumor-bearing animals | PIM1, PIM2, PIM3 | ALDH1A1 984/4885KDM4E 820/4885HPGD 1027/4885 |
| US-20080161559-A1 | PIM KINASE INHIBITORS AS CANCER CHEMOTHERAPEUTICS | PIM1, PIM3, PIM2 | ALDH1A1 1668/4885KDM4E 1232/4885HPGD 1749/4885 |
| US-20090030196-A1 | PIM KINASE INHIBITORS AS CANCER CHEMOTHERAPEUTICS | PIM1, PIM3, PIM2 | ALDH1A1 1668/4885KDM4E 1232/4885HPGD 1749/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.